Using QSP Models to Evaluate the Clinical Development Path

Pfizer was investigating inhibitors of the enzyme fatty acid amide hydrolase (FAAH) as a treatment for pain. FAAH degrades the endogenous cannabinoid—anandamide (AEA), which is a CB-1 and CB-2 cannabinoid receptor agonist. Increased levels of anandamide attenuate firing of pain-sensing neurons (nociceptors). Pfizer’s clinical pharmacology team wanted to know whether the proposed doses of FAAHi PF-04457845, a potent FAAH inhibitor in development for treating pain, would test the pharmacology fully. Read this case study to learn how a quantitative systems pharmacology approach (QSP) with internal and external data was used to address this and other questions.

Fill out the form to download our case study now!

Additional text can go here...